Full Press Release Details
Affimed Announces Listing Transfer to NASDAQ Capital Markets
Mannheim, Germany, October 4, 2023 Affimed N.V. (Nasdaq: AFMD) ( Affimed , or the Company ), a
clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received approval from the Listing Qualifications Department of the Nasdaq Stock Market ( Nasdaq )
to transfer the listing of its shares from the Nasdaq Global Market to the Nasdaq Capital Market. This transfer is effective as of the opening of business on October 4, 2023.
This announcement has no immediate effect on the listing or trading of the Company s common shares. The Company s shares will continue to trade
under the AFMD ticker symbol. The approval by Nasdaq was conditioned upon the Company meeting the applicable market value requirement of publicly held shares for continued listing and all other applicable requirements for listing on the
Nasdaq Capital Market.
In connection with the transfer to the Nasdaq Capital Market, the Company became eligible for an additional 180-day period (or until April 1, 2024) to regain compliance with the requirement set forth in Nasdaq Listing Rule 5450(a)(1) that the bid price of the Company s shares meet or exceed $1.00 per share for
at least ten consecutive business days (the Minimum Bid Price Rule ). The Company intends to continue to monitor the bid price of its common shares and consider available options to regain compliance with the Minimum Bid Price Rule.
Affimed (Nasdaq: AFMD) is a
clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination
therapy programs. The ROCK platform predictably generates customized innate cell engager (ICE ) molecules, which use patients
immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE . Headquartered in Mannheim, Germany, with offices in New
York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients lives. For more about the Company s people, pipeline and partners, please
visit: www.affimed.com.
Forward Looking Statements
This report contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often
indicated by terms such as anticipate, believe, could, estimate, expect, goal, intend, look forward to, may, plan,
potential, predict, project, should, will, would and similar expressions. Actual results may differ materially from the results anticipated by the Company s forward-looking
statements due to certain risks, uncertainties and other factors described under the heading Risk Factors in Affimed s filings with the SEC. Given these risks, uncertainties, and other factors, you should not place undue reliance on
these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.
Investor Relations Contact
Director, Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102